Royalty Pharma's total assets for Q1 2026 were $19.82B, an increase of 0.99% from the previous quarter. RPRX total liabilities were $9.88B for the fiscal quarter, a -0.28% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.